Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 776 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... May 5, 2021 Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... August 27, 2021 Alternatives for Outdoor Foods October 16, 2020 Load more HOT NEWS Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Hopes for the future of cancer research – a video from... Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a...
